Huidige behandeling van gemetastaseerde wekedelentumoren

Current treatment of metastatic soft tissue sarcoma Introduction: Soft tissue sarcomas are a rare, yet heterogeneous group of connective tissue tumors in which metastases frequently occur. Due to their complexity and heterogeneity, the prognosis is often poor. This literature review aims to provide an overview of the available therapies for 5 interesting subtypes in patients with metastases. Methods: A literature review based on systematic reviews, meta-analysis and reviews. Through backward search some smaller studies were included. Results: Results indicate that doxorubicin remains the standard treatment for metastatic soft tissue tumors, regardless of histology. On an individual basis, it can be chosen to add ifosfamide. Second-line therapy is more specific by subtype. Immunotherapy and targeted molecular therapy are currently being studied. Discussion: While doxorubicin remains the first choice for systemic treatment, more research into subtype-specific therapies is required for more effective treatments with fewer toxicities. Further investigation into immunotherapy and targeted molecular therapies is required.